Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
Takeda Pharmaceutical’s ALK inhibitor Alunbrig (brigatinib) slashes the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori (crizotinib) in previously untreated patients with ALK-positive non-small cell lung cancer (NSCLC), latest data show. The interim results…
To read the full story
Related Article
- Alunbrig Beats Xalkori in Front-Line NSCLC: Takeda
July 26, 2018
BUSINESS
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…